<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110996">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968265</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 426115-CS2</org_study_id>
    <secondary_id>2013-002172-40</secondary_id>
    <nct_id>NCT01968265</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutaneously Once Weekly for 6 Weeks to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isis Pharmaceuticals</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Romania: Ministry of Public Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of
      ISIS-GCCRRx in combination with metformin versus placebo + metformin
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The effect of ISIS-GCCRRx on serum fructosamine</measure>
    <time_frame>7 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline to Week 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of ISIS-GCCRRx</measure>
    <time_frame>18 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>By determining the incidence, severity, adverse effects, and changes in laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The tolerability of ISIS-GCCRRx</measure>
    <time_frame>18 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>By determining the incidence, severity, adverse effects, and changes in laboratory evaluations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ISIS-GCCRRx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS-GCCRRx</intervention_name>
    <description>3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin</description>
    <arm_group_label>ISIS-GCCRRx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 18 to 75

          -  BMI greater than or equal to 25

          -  HbA1c greater than or equal to 7.5% and less than or equal to 10.5%

          -  Type 2 Diabetes Mellitus and on stable dose of oral metformin

          -  Agree to conduct home-based (fasted) blood glucose testing as directed

        Exclusion Criteria:

          -  Clinically significant abnormalities in medical history or physical exam

          -  Show evidence of uncorrected hypothyroidism or hyperthyroidism hormone results

          -  History of renal transplantation or renal dialysis

          -  History of liver disease

          -  History of greater than 3 episodes of severe hypoglycemia within 6 months of
             screening

          -  Use of oral anti-diabetic medication other than metformin within 3 months of
             screening

          -  Use of medications that may affect plasma glucose levels (including systemic
             glucocorticoids), systemic steroids, corticosteroids, antiglucocorticoid therapies
             including mifepristone and ketoconazole (topical cream and systemic),
             immunosuppressive medications, somatostatin analogues or ACTH therapy within 3 months
             of screening

          -  History of diabetic ketoacidosis

          -  Current or previous diagnosis of Gilbert's  disease

          -  Any other significant illness or condition that may interfere with the patient
             participating or completing the study

          -  Inability or unwillingness to comply with protocol or study procedures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Isis Pharmaceuticals, Inc.</last_name>
    <phone>1-800-679-4747</phone>
    <email>patients@isisph.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Isis Investigative Site</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Isis Investigative Site</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Isis Investigative Site</name>
      <address>
        <city>Cornwall</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Isis Investigative Site</name>
      <address>
        <city>Courtice</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Isis Investigative Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 22, 2013</lastchanged_date>
  <firstreceived_date>October 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>T2DM</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
